Shots:
- The US FDA has granted Breakthrough Device Designation to SimpleScreen Lung to detect early signals of lung cancer in a blood sample from a standard blood draw
- SimpleScreen Lung builds on its base-level methylation & next-generation sequencing platform, combining methylation & proteomics with an AI/ML-powered classifier to detect lung cancer signals
- Freenome presented initial development data for the investigational SimpleScreen Lung test at the AACR’26 & is continuing its clinical evaluation through the prospective PROACT LUNG study
Ref: Globenewswire | Image: Freenome | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us atconnect@pharmashots.com
